Comparison of the selection of antimicrobial resistance in fecal Escherichia coli during enrofloxacin administration with a local drug delivery system or with intramuscular injections in a swine model.
This study evaluated, for the first time, the selection of antibiotic resistance in fecal Escherichia coli, a potential reservoir of genes of resistance, during the prolonged exposure to fluoroquinolones after the implantation of a local drug delivery system (LDDS) in a swine model. Fourteen pigs were randomly assigned to group IM (5 mg/kg/day of intramuscular enrofloxacin--EFX) or LD (surgical implantation of EFX-polymethyl-methacrylate peri-femoral implants). Blood samples were collected daily for determination of plasma EFX and ciprofloxacin (CFX) concentrations. Fecal samples were collected daily to determine the E. coli counts and the susceptibility patterns of its isolates as evaluated by antibiotic disk diffusion tests. In both groups, EFX administration significantly reduced the bacterial counts after 2 days. During recolonization, the bacterial counts remained lower than baseline in group IM but not significantly, and almost reached pre-treatment levels in group LD. Susceptibility to EFX, CFX, and nalidixic acid of recolonizing E. coli in LD pigs slightly decreased but remained within the limit of "susceptible" isolates. In contrast, quinolone susceptibility of recolonizing E. coli in IM pigs dropped dramatically (P < 0.0001). In addition, intramuscular exposure to fluoroquinolones significantly decreased the susceptibility of E. coli to ampicillin and trimethoprim-sulfamethoxazole (P < 0.05). In conclusion, the use of a dosing regimen that minimized the intestinal output of fluoroquinolones also minimized the selection of resistance to several classes of antibiotics. This could represent another advantage of LDDS usage compared to long-lasting systemic administration of fluoroquinolones.
Béraud
Romain
R
Department of Clinical Sciences, Faculté de Médecine Vétérinaire, Université de Montréal. romain.beraud@umontreal.ca
Huneault
Louis
L
Bernier
Dave
D
Beaudry
Francis
F
Letellier
Ann
A
del Castillo
Jérôme R E
JR
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D004197:Disease Reservoirs / Q000662:veterinary; D004343:Drug Implants; D024881:Drug Resistance, Bacterial; D000077422:Enrofloxacin; D004926:Escherichia coli / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary*; D005243:Feces / Q000382:microbiology*; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D007273:Injections, Intramuscular / Q000662:veterinary; D008826:Microbial Sensitivity Tests / Q000662:veterinary; D011897:Random Allocation; D012641:Selection, Genetic; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy* / Q000382:microbiology; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D004343:Drug Implants; D024841:Fluoroquinolones; D000077422:Enrofloxacin
J Antimicrob Chemother. 1992 Apr;29(4):415-25
1607330
Vet Clin North Am Small Anim Pract. 1991 Jul;21(4):781-811
1897086
Vet Surg. 2000 Sep-Oct;29(5):375-82
10999450
J Antimicrob Chemother. 2004 Feb;53(2):252-7
14688048
J Antimicrob Chemother. 2003 Oct;52(4):645-50
12972454
Clin Orthop Relat Res. 1990 Dec;(261):126-33
2173986
J Hosp Infect. 1988 Aug;12(2):103-8
2905712
Vet Microbiol. 2007 Jan 31;119(2-4):304-10
16987619
Can J Vet Res. 2002 Apr;66(2):86-92
11989739
Drugs. 2000 Jun;59(6):1223-32
10882159
Med Microbiol Immunol. 1978;164(4):247-53
45599
Clin Orthop Relat Res. 1992 May;(278):244-52
1563160
Clin Orthop Relat Res. 2006 Apr;445:239-44
16474225
Clin Infect Dis. 2001 Sep 15;33 Suppl 3:S147-56
11524712
Acta Orthop Scand. 1992 Dec;63(6):661-4
1471518
Vet Surg. 2003 May-Jun;32(3):251-61
12784202
Vet Comp Orthop Traumatol. 2006;19(2):106-9
16810353
Microb Drug Resist. 1998 Winter;4(4):289-99
9988047
Clin Pharmacokinet. 1995 Jul;29(1):36-45
7586897
Epidemiol Infect. 1993 Oct;111(2):221-8
8405150
Drug Resist Updat. 1999 Feb;2(1):38-55
11504468
J Antimicrob Chemother. 1999 Mar;43 Suppl A:31-40
10225569
J Pharmacokinet Biopharm. 1978 Dec;6(6):547-58
731417
Res Vet Sci. 2003 Dec;75(3):185-93
13129666
Vet Res. 2001 May-Aug;32(3-4):227-41
11432415
J Orthop Res. 1994 Jan;12(1):79-82
8113945
J Antimicrob Chemother. 2006 Jun;57(6):1116-21
16624874
Clin Infect Dis. 1997 Jan;24 Suppl 1:S67-73
8994781
Br J Pharmacol. 1997 Aug;121(8):1567-78
9283689
J Am Vet Med Assoc. 2001 Jul 1;219(1):40-8
11439768
Acta Orthop Scand. 2001 Dec;72(6):557-71
11817870
Clin Orthop Relat Res. 1996 Aug;(329):273-80
8769462
Drugs. 1999;58 Suppl 2:11-8
10553699
Int J Antimicrob Agents. 2005 Dec;26(6):473-8
16280241
J Antimicrob Chemother. 2003 Jul;52(1):11-7
12805267
J Orthop Res. 2004 Nov;22(6):1351-7
15475220
Biomaterials. 2002 Mar;23(6):1495-502
11829446
J Bone Joint Surg Br. 2002 Jul;84(5):758-60
12188500
Clin Podiatr Med Surg. 1996 Oct;13(4):701-24
9026404
Clin Orthop Relat Res. 1986 Oct;(211):108-15
3769249
J Infect Dis. 2004 Apr 1;189(7):1291-4
15031799